British Approved Name
A British Approved Name (BAN) is the official non-proprietary or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP).
The BAN is also the official name used in some countries across the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming consistency worldwide.
BANs are unique in that names are assigned for combination preparations as well as single-drug preparations. For example, the BAN Co-amoxiclav is assigned to preparations containing amoxicillin and clavulanic acid. Most other pharmacopoeias simply refer to combination products by both ingredients in the preparation, in this example "amoxicillin with clavulanic acid".
The prefix of "co-" is used for many combination drugs, including opioid with paracetamol or aspirin analgesics (e.g., Co-codamol, Co-codaprin, Co-dydramol, Co-proxamol). The other commonly encountered opioid combination is the anti-diarrhoeal, non-analgesic mixture of diphenoxylate and atropine, Co-phenotrope (a.k.a. Lomotil). Also antibiotics (e.g., Co-fluampicil and Co-trimoxazole), drugs to lower blood pressure (e.g., Co-tenidone), diuretics (e.g., Co-amilofruse and Co-amilozide), gastrointestinal drugs (e.g., Co-danthrusate), and anti-Parkinsonism agents such as Co-careldopa, Co-beneldopa, and others (e.g., Co-cyprindiol).
European Union legislation from 2001 required harmonisation of the BP with the European Pharmacopoeia (EP), as well as the adoption of International Nonproprietary Names through directives (2001/82/EC  and 2001/83/EC, as amended, and 2003/63/EC ). Across the EU has meant that, with the notable exception of adrenaline/epinephrine, BANs are now the same as the INNs.
This has resulted in an interesting situation in countries such as Australia. While the British Pharmacopoeia and BANs are the official pharmacopoeia/names defined by legislation in these countries, the former-BANs continue to be used, purportedly because of the difficulty of changeover. Despite the importance of the BP there appears to be little or no movement in the direction of changing these names.
- Mr Anthony C Cartwright (28 June 2015). The British Pharmacopoeia, 1864 to 2014: Medicines, International Standards and the State. Ashgate Publishing, Ltd. pp. 155–. ISBN 978-1-4724-2032-9.
- Aronson, JK (19 February 2000). ""Where name and image meet"--the argument for "adrenaline".". BMJ (Clinical research ed.) 320 (7233): 506–9. PMID 10678871.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|